The Federal Trade Commission settles a complaint against ZyCal Bioceuticals Healthcare Company Inc. about claims that its Ostinol hydrolyzed collagen dietary supplements grow bone and cartilage to relieve joint pain.
Hydrolyzed Collagen Supplement Firm Agrees To Order Barring Claims To Grow Bone, Cartilage
Claims of bone and cartilage growth, along with relief of joint pain, shot down by FTC. But company says claims “are adequately substantiated by existing studies and scientific literature.”
More from Legal
In response to an IPA Europe complaint, European Ombudsman Emily O’Reilly finds that the Commission’s interpretation of EU food legislation in relation to probiotics is “reasonable and in line with the main goal of this legislation, which is to ensure a high level of consumer protection.”
Despite questions surrounding the SEC rule, including disputes being litigated in the US Eighth Circuit, companies must prepare to meet the new climate disclosure requirements in addition to related mandates in California and abroad. Experts emphasize opportunities beyond compliance.
Report from European Commission's Alert and Cooperation Network finds EU consumers are being deceived by companies marketing supplements making unauthorized health claims and containing unapproved ingredients.
The Supreme Court’s 6-3 ruling is expected to have a minimal impact on drug approvals and other scientific determinations, but matters steeped in the interpretation of regulation and statute, such as marketing exclusivity, could face a heightened risk of challenge, legal experts say.